What FDA reviewers look for in translated submissions, terminology inconsistencies that trigger rejection, and why 510(k) translation requires domain expertise.
- Where the translation requirement comes from
- Consistency is what gets noticed
- Traceability
Where the translation requirement comes from
FDA submissions are made in English. The translation requirement arises when your underlying material — design history, clinical data, quality records, supplier documentation — was authored in another language and has to be presented in English.
Requirements differ by device class and submission pathway. Confirm the specifics for your submission with your regulatory consultant; this article covers the translation practice, not the regulatory strategy.
Consistency is what gets noticed
A reviewer reads a submission as a set. When the device is described one way in the indications, another in the labelling and a third in the test reports, the discrepancy becomes a question — and questions consume review cycles.
Most avoidable friction we see comes from documents translated at different times by different hands, with no shared terminology. The fix is unglamorous: lock the terms first, against your existing approved labelling.
Traceability
A quality system expects a documented process with accountable steps. Text of unclear provenance — including unreviewed machine output — is harder to defend if the process is examined, regardless of whether the text happens to be correct.
Regulatory content therefore runs through domain expert review and a QA audit, and the process is documented.